Related Experiment Video
Updated: Jun 16, 2025
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
233
Correlation Between Oncotype Dx Recurrence Score and PREDICT Estimates in Early Breast Cancer: A Single Institution
Ezzeldin M Ibrahim1, Bushra A Al-Quzi2, Ahmed Y Shaheen2
1Oncology Department, King's College London-Jeddah, Jeddah, Kingdom of Saudi Arabia.
JCO Global Oncology
|August 19, 2024
Summary
The Oncotype Dx Recurrence Score (RS) and PREDICT tool show significant discordance in estimating chemotherapy benefits for early breast cancer patients. PREDICT cannot replace RS for predicting adjuvant chemotherapy benefits.
Area of Science:
- Oncology
- Genomics
- Precision Medicine
Background:
- The Oncotype Dx Recurrence Score (RS) is a key prognostic and predictive tool for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer.
- The cost of RS testing can be a barrier, prompting interest in accessible alternatives like the PREDICT tool.
Purpose of the Study:
- To assess the correlation between Oncotype Dx Recurrence Score (RS) and the PREDICT tool's estimation of adjuvant chemotherapy benefit.
- To evaluate the concordance between these two methods in predicting treatment outcomes for early-stage breast cancer.
Main Methods:
- Retrospective review of 112 patients with HR+, HER2- early breast cancer.
- Analysis of correlations between RS values and PREDICT tool estimations using Spearman rank and McNemar tests.
Main Results:
- Significant positive correlation found between absolute RS values and predicted chemotherapy benefit by PREDICT.
- High discordance rates (48-67%) observed between RS-based and PREDICT-based risk assignments.
- No significant correlation found in the percentage of chemotherapy gain between the two methods.
Conclusions:
- Significant discordance exists between RS and PREDICT tools in predicting adjuvant chemotherapy benefits for HR+, HER2- early breast cancer.
- The PREDICT tool cannot substitute for RS in guiding chemotherapy decisions.
- Further research is needed to optimize precision medicine in breast cancer management.
Related Concept Videos
01:21Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
01:15Receiver Operating Characteristic Plot
106
A ROC (Receiver Operating Characteristic) plot is a graphical tool used to assess the performance of a binary classification model by illustrating the trade-off between sensitivity (true positive rate) and specificity (false positive rate). By plotting sensitivity against 1 - specificity across various threshold settings, the ROC curve shows how well the model distinguishes between classes, with a curve closer to the top-left corner indicating a more accurate model. The area under the ROC curve...
106
01:13Sensitivity, Specificity, and Predicted Value
228
In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
Sensitivity is the...
228